|Bid||121.75 x 900|
|Ask||121.86 x 1000|
|Day's Range||118.84 - 122.09|
|52 Week Range||75.72 - 157.10|
|Beta (5Y Monthly)||1.72|
|PE Ratio (TTM)||101.39|
|Earnings Date||Oct 28, 2020 - Nov 02, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Jan 09, 1992|
|1y Target Est||150.00|
The National Institutes of Health said it will conduct a randomized, controlled clinical trial testing a combination of Gilead Sciences Inc.'s remdesivir with Merck KGaA's interferon beta-1a as a treatment for COVID-19 patients. The study plans to enroll 1,000 people who have been hospitalized because of a COVID-19 infection. The federal agency said it expects to have preliminary results in the fall. Since the Food and Drug Administration granted an emergency use authorization to remdesivir in May, several clinical trials have been initiated that aim to pair the investigational therapy with other drugs to see if the combination can better treat severely ill COVID-19 patients. This includes another NIH trial pairing remdesivir with Eli Lilly & Co. and Incyte Corp. 's Olumiant. Roche Holding AG has also said it will test its rheumatoid arthritis drug in combination with remdesivir.
Rogers Corporation today announced the launch of Griswold GripON™, a next generation natural sponge solution designed to address slippage and skidding issues prominent within the electronics, furniture, automotive, and appliances industries. Engineered to reduce noise, minimize vibration, and eliminate the risk of scratching, Griswold GripON material provides stability and resistance to address sliding challenges presented in a multitude of markets.
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of March 31st, a week after the market trough. Now, we are […]